# Matthew J. Ellis, Ph.D., M.D.
Baylor College of Medicine, USA

Dr. Matthew James Ellis is a native of the United Kingdom. He completed his medical degree at Queens' College & School of Clinical Medicine at the University of Cambridge in England, postgraduate clinical training at the Royal College of Physicians in London and gained a Ph.D. at the Royal Postgraduate Medical School and Imperial Cancer Research Fund at the University of London.   After a medical oncology fellowship at the Lombardi Cancer Center, Georgetown University, Washington DC, he was an Assistant Professor there until moving to Duke University in 2000 and subsequently to Washington University in St Louis where he served as professor of medicine and section head of breast oncology until 2014.   Ellis was recently recruited to Baylor College of Medicine to serve as the Director of the Lester and Sue Smith Breast Center and to hold the C. Kent Osborne Chair of Breast Oncology. Both the McNair Foundation and the Cancer Prevention Research Institute of Texas recently awarded him scholarships. He has been instrumental in developing a Genome Atlas and Therapeutic Road Map for estrogen receptor positive breast cancer by applying genomic techniques to samples accrued through a series of neoadjuvant endocrine therapy trials.   Most recently, he has found that metastatic breast tumors harbor mutations and translocations in the estrogen receptor gene that render the tumor resistant to therapies used to block estrogen receptor function.  He also pioneered research into the clinical relevance of activating mutations in HER2 and in the deployment of patient-derived xenografts for the pharmacological annotation of breast cancer genomes.  He is currently Co-Chair of the translational medicine committee for the NRG cooperative group, co-leader for The Cancer Genome Atlas (TCGA) Breast Project and also serves as a Co-PI for the Clinical Proteomic Tumor Analysis Consortium that endeavors to translate TCGA genomic discoveries into protein-based biomarkers with clinical utility.   Dr. Ellis has a successful track record in international clinical and translational research, with recent trainees from Brazil, Chile, Poland and Turkey.

## Specialty & Research Field of Interest
Translational Breast Cancer Genomics and Proteomics

## Selected Publications
1. Bose R, Kavuri SM, Searleman AC, Shen W, Shen D, Koboldt DC, Monsey J, Goel N, Aronson AB, Li S, M.J. Ellis. Activating HER2 mutations in HER2 gene amplification negative breast cancer. **Cancer Discov**. 2013; 3(2): 224-37.
2. Ellis MJ, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. **Nature.** 2012; 486(7403): 353-60
3. Ellis MJ, et al. Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. **Cancer Discov.** 2013; 3(10): 1108-12.